MXT-002™ is a fraction of Wharton's jelly created specifically for the cosmetic market.  Wharton's jelly is a viscous, gelatinous substance found in the umbilical cord of human newborns.

LILIUM's MXT-002™ is harvested from human umbilical cords collected by US recovery agencies following AATB, FDA, and CDC guidelines during full-term, healthy Cesarean births with maternal consent.

MXT-002™ is processed using proprietary technology at Neobiosis®. No enzymes are used in the processing of MXT-002™

MXT-002™ contains a rich source of natural collagen, hyaluronic acid, chondroitin sulfate, exosomes, and over 200 distinct, biologically active cytokines and growth factors.

The unique composition of MXT-002™ makes it a valuable ingredient for promoting vitality and helping to aid in a youthful transformation.

PSF-003™ is a specific fraction of purified amniotic fluid which contains approximately 350 billion exosomes per cc, over 300 biologically active cytokines and growth factors, RNAs, mRNA’s, natural human-derived Hyaluronic acid, Chondroitin Sulfate, and Klotho. Lilium Pure™ and Lilium One™ are derived from a specific fraction of PAF - PSF-003™.

LILIUM's PSF-003™ is harvested from human amniotic fluid collected by US recovery agencies following AATB, FDA, and CDC guidelines during full-term, healthy Cesarean births with maternal consent.

PSF-003™ is purified in state-of-the-art cleanrooms at Neobiosis® laboratories.

Lilium Pure ™ and Lilium One ™ are derived from a specific fraction of purified amniotic fluid called PSF-003™. PSF-003™ contains billions of exosomes, over 300 distinct, biologically active cytokines and growth factors, lipids, RNAs, mRNAs, abundant human-derived hyaluronic acid, and Klotho.

Amniotic fluid is collected with full maternal consent during Cesarean births.

Donor serological testing is performed by an independent lab that is registered with the FDA as an establishment for testing and certified to perform such testing on human specimens in accordance with Clinical Laboratory Improvement Amendment of 1988 (CLIA) and 47 CFR Part 493, or that determine by the Center for Medicare and Medicaid Services (CMS). Testing is performed using FDA-approved test kits.